All In Biotech

Drug Trial Radar · NCT03920007

Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D

A Phase 1/2 Dose Escalation Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D

Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

15

Actual

Start

Oct 22, 2019

Primary completion

May 19, 2023

Study completion May 19, 2027

Sponsor

Lead sponsor
Atsena Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Apr 18, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To evaluate the safety and tolerability of ascending doses of ATSN-101 administered as a unilateral subretinal injection in patients with Leber Congenital Amaurosis (LCA) caused by autosomal recessive guanylate cyclase 2D (GUCY2D) mutations (GUCY2D-LCA). Secondary Objective: To evaluate the efficacy of ascending doses of ATSN-101 administered as a unilateral subretinal injection in patients with GUCY2D-LCA.

Conditions

  • Leber Congenital Amaurosis
  • LCA
  • LCA1

Interventions

  • ATSN-101Drug

    Pharmaceutical form:Solution for intraocular administration Route of administration: Subretinal injection

  • ATSN-101 Diluent SolutionDrug

    Pharmaceutical form:Solution for parenteral use Route of administration: Subretinal injection

  • PrednisoneDrug

    Pharmaceutical form:Tablet Route of administration: Oral

  • Triamcinalone AcetonideDrug

    Pharmaceutical form:Suspension Route of administration: Peri-ocular injection

  • 1% PrednisoloneDrug

    Pharmaceutical form:Suspension Route of administration: Drops

  • Trimethoprim/polymyxin BDrug

    Pharmaceutical form:Solution Route of administration: Topical

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs) From Baseline up to the End of the Observation PeriodTime frame: From Baseline to Week 52

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Casey Eye Institute - Oregon Health & Science University

    Portland, Oregon

  • Scheie Eye Institute, University of Pennsylvania

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.